Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
AIMS: The aim of this study is to explore whether administration timing affects glycaemic control by lixisenatide once-daily in type 2 diabetes mellitus (T2DM). METHODS: A phase IIIb, open-label, 1:1 randomized, active-controlled, 24-week multicentre study of T2DM patients inadequately controlled on metformin was conducted. Patients were administered lixisenatide before breakfast or the main meal. The primary endpoint was change from baseline at week 24 in glycated haemoglobin (HbA1c). Other endpoints: changes in body weight, fasting plasma glucose (FPG), 7-point self-monitored plasma glucose (SMPG) and Diabetes Treatment Satisfaction Questionnaire status (DTSQs) score. Adverse events (AEs) were monitored. RESULTS: Mean change in HbA1c from baseline at week 24 was -0.65% (-7.1mmol/mol; main meal) and -0.74% (-8.1mmol/mol; breakfast). Mean changes in FPG, body weight and DTSQs score were comparable between groups. The mean change in body weight (kg) was -2.60 (main meal) and -2.80 (breakfast group). The 7-point SMPG profiles showed greatest reductions in postprandial glucose after the meal at which lixisenatide was administered, with a residual effect seen on the subsequent meal. AE rates were similar between groups, including gastrointestinal AEs. CONCLUSIONS: Lixisenatide before the main meal was noninferior to lixisenatide before breakfast in patients insufficiently controlled on metformin. Lixisenatide treatment allows flexibility in administration timing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s067 · Cited by 2,245
Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288
Self-citationRosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Boden, G., Chen, X., & Urbain, J. L. (1996) · Diabetes · doi:10.2337/diab.45.8.1044 · Cited by 228 · cited 1×
“Morning hyperglycaemia is thought to occur due to a deficit in insulin secretion in patients with T2DM, acting in concert with circadian variations in hepatic glucose output, which peaks in the early morning due to overnight fasting [4,5].”
BackgroundEfficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Ahrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., & Aronson, R. (2013) · Diabetes Care · doi:10.2337/dc12-2006 · Cited by 172 · cited 3×
“As such, although the improved glycaemia versus placebo was similar in the two groups, direct comparisons between morning and evening lixisenatide dosing could not be drawn [10].”
BackgroundInfluentialSelf-citationBolli, G. B., Munteanu, M., Dotsenko, S., Niemoeller, E., Boka, G., Wu, Y., & Hanefeld, M. (2014) · Diabetic Medicine · doi:10.1111/dme.12328 · Cited by 144
Cited by
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
Christensen, M., Miossec, P., Larsen, B. D., Werner, U., & Knop, F. K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.942638 · Cited by 34
Incretin and Islet Hormone Responses to Meals of Increasing Size in Healthy Subjects
Alsalim, W., Omar, B., Pacini, G., Bizzotto, R., Mari, A., & Ahrén, B. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2865 · Cited by 33
“This is important because 260- and 520-kcal meals are not representative of a normal lunch or dinner, when most subjects ingest their highest caloric meal (6).”
BackgroundOnishi, Y., Niemoeller, E., Ikeda, Y., Takagi, H., Yabe, D., & Seino, Y. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12275 · Cited by 13
Metadata
- Authors
- Ahrén, B., Vorokhobina, N., Souhami, E., Demil, N., Ye, J., & Aronson, R.
- Venue
- Journal of Diabetes and its Complications
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 28
- Issue
- 5
- Pages
- 735-741
- ISSN
- 0891-6632 (ISSN-L)
- 1056-8727
- OpenAlex
- W2118929450
- Cited by
- 19
- References
- 7
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.